| Keywords: |
vasculotropin; cancer survival; treatment outcome; treatment response; sorafenib; bevacizumab; cisplatin; doxorubicin; erlotinib; fluorouracil; interferon; placebo; sunitinib; advanced cancer; cancer combination chemotherapy; cancer growth; chemoembolization; drug efficacy; drug safety; liver cell carcinoma; liver function; liver transplantation; treatment duration; unspecified side effect; carcinoma, hepatocellular; liver neoplasms; cancer adjuvant therapy; progression free survival; multiple cycle treatment; tumor volume; antineoplastic combined chemotherapy protocols; editorial; angiogenesis; retrospective study; cancer mortality; liver failure; antiangiogenic therapy; upregulation; inoperable cancer; cancer control; hypoxia inducible factor 1alpha; phase 2 clinical trial (topic); meta analysis (topic); phase 3 clinical trial (topic); tumor necrosis; gastrointestinal tumor; chemoembolization, therapeutic; invasive procedure
|
